|
|
Á¦¸ñ :
[Áö¿£Æ¼Æĸ¶]23.01.02ÀÏÀÚ ¿Ü½Å±â»ç(¹Ì±¹ 3»ó ³úÁ¹Áß °ü·Ã) |
|
±Û¾´ÀÌ : Áö¿£Æ¼Æĸ¶ |
ÀÛ¼ºÀÏ : 2023-01-04 15:46:58 |
Á¶È¸¼ö : 1210
|
|
|
|
Nelonemdaz, what is the likelihood that the drug will be approved?
Nelonemdaz is under clinical development by GNT Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Nelonemdaz¡¯s likelihood of approval (LoA) and phase transition for Burns took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 27 Dec 2022 increased Nelonemdaz¡¯s Phase Transition Success Rate (PTSR) for Traumatic Spinal Cord Injury.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nelonemdaz LoA and PTSR Report.
Nelonemdaz overview
Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction. It is administered intravenously. It acts by targeting both NR2B-specific N-methyl-D-aspartate (NMDA) receptor and oxidative stress.
GNT Pharma overview
GNT Pharma (GNT Pharma Co) that manufactures botanical-based medicine, nutraceuticals, over-the-counter drugs, and veterinary medicine. The company is headquartered in Seongnam, Kyonggi-do, South Korea.
Quick View Nelonemdaz LOA Data
³Ú·Î³Û´ÙÁî, ±× ¾àÀÌ ½ÂÀ뵃 °¡´É¼ºÀº ¾ó¸¶³ª µË´Ï±î?
Nelonemdaz´Â GNT Pharma¿¡ ÀÇÇØ ÀÓ»ó °³¹ß ÁßÀ̸ç ÇöÀç ÀÓ»ó °æ·Î¿¡¼ 1´Ü°è¿¡ ÀÖ´Ù. ÀÓ»ó½ÃÇèÀÇ Æ¯¼º»Ó¸¸ ¾Æ´Ï¶ó ÀǾàÇ°, ±ÔÁ¤ ¹× ȸ»ç¿Í °ü·ÃµÈ ±âŸ ¼Ó¼ºÀº ÀǾàÇ°ÀÌ ÇöÀçÀÇ °³¹ß ´Ü°è¿¡¼ ´ÙÀ½ ´Ü°è·Î À̵¿ÇÒ ¼ö ÀÖ´Â Àüȯ °¡´É¼ºÀ» º¸ÀåÇÏ´Â µ¥ ±Ùº»ÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù.
±Û·Î¹ú µ¥ÀÌÅÍ¿¡ µû¸£¸é, NelonemdazÀÇ ½ÂÀÎ °¡´É¼º(LoA) ¹× ¹øÁî¿¡ ´ëÇÑ »óÀüÀÌ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÃֽŠÀ̺¥Æ®°¡ 2022³â 12¿ù 27ÀÏ¿¡ ¹ß»ýÇßÀ¸¸ç, ÀÌ´Â ¾à¹°ÀÌ ÀÓ»ó °æ·Î¿¡¼ ´ÙÀ½ ´Ü°è·Î ÁøÇàµÉ °¡´É¼ºÀ» Áõ°¡½ÃÄ×´Ù.
°Ô´Ù°¡, 2022³â 12¿ù 27ÀÏ °°Àº »ç°ÇÀº ¿Ü»ó¼º ô¼ö ¼Õ»ó¿¡ ´ëÇÑ ³Ú·Î³Û´ÙÁîÀÇ »óÀüÀÌ ¼º°ø·ü(PTSR)À» Áõ°¡½ÃÄ×´Ù.
Global Data´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í ºÐ¼®À» »ç¿ëÇÏ¿© Nelonemdaz LoA ¹× PTSR º¸°í¼¿¡¼ ÀÌ Æò°¡ÀÇ Àüü ±×¸²À» Á¦°øÇÕ´Ï´Ù.
Nelonemdaz °³¿ä
Neuronemdaz(Neu2000)´Â ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß, ¿Ü»ó¼º ³ú¼Õ»ó, ¿Ü»ó¼º ô¼ö¼Õ»ó, ±Þ¼º ½É±Ù°æ»ö(AMI) ¹× È»ó¼Õ»ó, ³ú°æ»öÀÇ Ä¡·á¸¦ À§ÇØ °³¹ß ÁßÀÌ´Ù. Á¤¸Æ ÁÖ»ç·Î Åõ¿©µÈ´Ù. NR2B ƯÀÌÀû N-¸ÞÆ¿-D-¾Æ½ºÆĸ£Æ®»ê(NMDA) ¼ö¿ëü¿Í »êÈ ½ºÆ®·¹½º¸¦ ¸ðµÎ Ç¥ÀûÈÇÔÀ¸·Î½á ÀÛ¿ëÇÑ´Ù.
GNT Á¦¾à °³¿ä
½Ä¹° ±â¹Ý ÀǾàÇ°, ¿µ¾çÁ¦, ó¹æÀü ¾øÀÌ »ì ¼ö ÀÖ´Â ÀǾàÇ°, ¼öÀÇÇÐÀ» Á¦Á¶ÇÏ´Â GNT Pharma (GNT Pharma Co.). º»»ç´Â ´ëÇѹα¹ °æ±âµµ ¼º³²½Ã¿¡ ÀÖ´Ù.
ºü¸¥ º¸±â Nelonemdaz LOA µ¥ÀÌÅÍ
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData¡¯s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs¡¯ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData¡¯s Pharmaceutical Intelligence Center.
¾÷°è ÃÖ°íÀÇ Á¤º¸ Á¦°ø¾÷üÀÎ ±Û·Î¹ú µ¥ÀÌÅÍ´Â ÀÌ ±â»ç¸¦ ÀÛ¼ºÇÏ´Â µ¥ »ç¿ëµÇ´Â ±âº» µ¥ÀÌÅÍ, ¿¬±¸ ¹× ºÐ¼®À» Á¦°øÇß½À´Ï´Ù.
±Û·Î¹ú µ¥ÀÌÅÍÀÇ ½ÂÀÎ °¡´É¼º ºÐ¼® µµ±¸´Â ÀǾàÇ°ÀÌ ÀÓ»ó °æ·Î(PTSR)¿¡¼ ´ÙÀ½ ´Ü°è·Î À̵¿ÇÒ °¡´É¼º°ú ÀǾàÇ° ½ÂÀÎ °¡´É¼º(LoA)À» µ¿ÀûÀ¸·Î Æò°¡ÇÏ°í ¿¹ÃøÇÑ´Ù. ÀÌ´Â ±Û·Î¹ú µ¥ÀÌÅÍÀÇ Á¦¾à ÀÎÅÚ¸®Àü½º ¼¾ÅÍ¿¡¼ ¹ß°ßµÇ´Â ÀǾàÇ°ÀÇ ÆǸŠ¿¹Ãø, ±ÔÁ¦ ¸¶ÀϽºÅæ, ºñ¿ë ¿¹Ãø, WACC ºñÀ² ¹× ±âŸ µ¶Á¡ µ¥ÀÌÅÍ ¼Ò½º¸¦ ±â¹ÝÀ¸·Î ±¸ÃàµÈ µ¶Á¡ ¾Ë°í¸®µëÀ» ±â¹ÝÀ¸·Î ÇÑ´Ù.
Áö¿£Æ¼Æĸ¶ ÁÖÁÖµ¿È£È¸ ¹Ù·Î°¡±â
¡Ø Åä·Ð¹æÀÇ ±ÛÀº ³×ƼÁðÀÌ ÀÛ¼ºÇÑ ±Û·Î ´ç»ç¿Í ÀüÇô ¹«°üÇϸç ÃÖÁ¾Ã¥ÀÓÀº ÀÌ¿ëÀÚ¿¡°Ô ÀÖ½À´Ï´Ù. |
|
|
|
|
|
|
|
[Áö¿£Æ¼Æĸ¶]23.01.02ÀÏÀÚ ¿Ü½Å±â»ç(¹Ì±¹ 3»ó ³úÁ¹Áß °ü·Ã),
Loading Time [ 0.06 Sec ] stock |
|
ºñ»óÀåÁֽİŷ¡, Àå¿ÜÁֽĽÃÀå NO.1 38Ä¿¹Â´ÏÄÉÀÌ¼Ç (http://www.38.co.kr)
±¤°í ¹®ÀÇ : ¢Ï 1644-3830 (38Ä¿¹Â´ÏÄÉÀ̼Ç) |
Àå¿ÜÁÖ½Ä,ºñ»óÀåÅä·Ð¹æ,Áö¿£Æ¼Æĸ¶ ÁÖÁÖÅä·Ð¹æ,Áö¿£Æ¼Æĸ¶ ±â¾÷°³¿ä,Áö¿£Æ¼Æĸ¶ ÇöÀç°¡,Áö¿£Æ¼Æĸ¶ ÁÖ°¡,Áö¿£Æ¼Æĸ¶ °ü·Ã´º½º,Áö¿£Æ¼Æĸ¶ ÁÖ½Ä,Áö¿£Æ¼Æĸ¶ ±â¾÷°¡Ä¡,Áö¿£Æ¼Æĸ¶ ½ÇÀû,Áö¿£Æ¼Æĸ¶ ÁÖ´ç¼øÀÌÀÍ,Áö¿£Æ¼Æĸ¶ ¸ÅÃâ,Áö¿£Æ¼Æĸ¶ »óÀå,38Ä¿¹Â´ÏÄÉÀ̼Ç,»ïÆÈÄ¿¹Â´ÏÄÉÀ̼Ç,38stock,38,ºñ»óÀå,ºñ»óÀåÁÖ½Ä,Àå¿ÜÁÖ½Ä,Àå¿Ü½ÃÀå,¼Ò¾×ÁÖÁÖ¸ðÀÓ,ÀÎÅͳݰø¸ð,ºñ»óÀåÁֽİŷ¡,Àå¿ÜÁֽĽü¼,Àå¿ÜÁֽİŷ¡,Àå¿Ü°Å·¡,ºñ»óÀåÁֽĸŸÅ,ºñ»óÀå½Ã¼¼,Àå¿Ü½Ã¼¼,Àå¿ÜÁֽĽÃÀå,ÁÖÁÖµ¿È£È¸,ºñ»óÀåÁֽĽü¼,Àå¿ÜÁֽĽÃȲ,IPO°ø¸ðÁÖ,ÀÎÅͳݰø¸ðÁÖ,IPO,»óÀ忹Á¤,½ºÆÑ,°ø¸ðÁÖ,±â¾÷°ø°³,°ø¸ð°ø¸ðû¾àÀÏÁ¤,½Å±Ô»óÀå,°ø¸ðÁÖû¾à,Àå¿Ü½ÃȲ,Àå¿ÜÁֽĽÃÀå,ºñ»óÀå»ç,ºñ»óÀåȸ»ç,ºñ»óÀå±â¾÷,ÇÁ¸®º¸µå,3½ÃÀå,ÄÚ½ºÄÞ,Äڳؽº,KONEX,KOSCOM,ÆŽº³Ý,Á¦3ÁֽĽÃÀå,KOSDAQ,KOSPI,»ï¼ºsds,Àå¿ÜÅõÀÚ,Àå¿ÜÁֽĻçÀÌÆ®,¼Ò¾×ÁÖÁÖ¸ðÀÓ,ºñ»óÀåÁֽİŷ¡»çÀÌÆ®
| |
|